

Denosumab - Xgeva



Included Products: Xgeva (denosumab)

Nonformulary for outpatient benefit. PA required on medical benefit.

Created: 03/10/2011

Revised: 05/10/2018

Reviewed: 05/10/2018

Updated: 09/08/2021

All Diagnoses

Initial Criteria		If yes	If no
1.	Does the member have a diagnosis of bone metastases from solid tumors or multiple myeloma?	Continue to #2.	Continue to #3.
2.	Has zoledronic acid been tried first or is there a contraindication to zoledronic acid that is not a contraindication to denosumab?	Continue to #6.	Do not approve.
3.	Does the member have a diagnosis of giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity?	Continue to #6.	Continue to #4.
4.	Does the member have a diagnosis of hypercalcemia of malignancy (HCM)?	Continue to #5.	Do not approve.
5.	Has a bisphosphonate such as zoledronic acid (Zometa) or pamidronate (Aredia) been tried first or is there a contraindication to either?	Continue to #6.	Do not approve.
6.	Approve 12 months.		